Nutritional/functional, laboratory, and quality of life variables evaluated after 1, 2, and 4 months of treatment on 39 patients
| Variables . | Baseline . | 1 mo . | P . | 2 mo . | P . | 4 mo . | P . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Body weight (kg) | 55.1 ± 10 | 56.5 ± 10.5 | 0.001 | 56.4 ± 9.7 | 0.036 | 57 ± 9.8 | 0.031 | |||||||
| LBM (kg) | 38 ± 9 | 38.9 ± 9 | 0.059 | 39.4 ± 8.9 | 0.045 | 39.7 ± 8.7 | 0.024 | |||||||
| Grip strength (kg) | 28.0 ± 10.4 | 27.8 ± 9.5 | 0.879 | 27.9 ± 9.3 | 0.673 | 28.1 ± 9.5 | 0.827 | |||||||
| Appetite | 5.5 ± 2.5 | 6.6 ± 2.2 | 0.005 | 6.8 ± 1.9 | 0.001 | 7.0 ± 1.6 | 0.004 | |||||||
| IL-6 (pg/mL) | 12.5 ± 9.9 | 8.8 ± 8.7 | 0.002 | 7.5 ± 8.6 | 0.003 | 7.4 ± 8.5 | 0.007 | |||||||
| TNF-α (pg/mL) | 22.2 ± 16.6 | 19.5 ± 16 | 0.204 | 15.8 ± 13 | 0.020 | 14 ± 11.7 | 0.015 | |||||||
| Leptin (ng/mL) | 5.9 ± 6.1 | 8.9 ± 10.6 | 0.008 | 10.2 ± 13.3 | 0.031 | 13.6 ± 13.3 | <0.001 | |||||||
| ROS (FORT U) | 468.5 ± 97.2 | 436.6 ± 92.5 | 0.033 | 437.7 ± 89.6 | 0.087 | 444.1 ± 93.6 | 0.162 | |||||||
| GPx (units/L) | 8,206.6 ± 2,322.3 | 8,339.3 ± 2,411.8 | 0.726 | 8,295.9 ± 2,314.1 | 0.848 | 8,849.2 ± 2,629 | 0.211 | |||||||
| Quality of life questionnaires | ||||||||||||||
| EORTC QLQ-C30 | 65.9 ± 16.3 | 72.4 ± 15.6 | 0.008 | 71.8 ± 14.6 | 0.020 | 70.9 ± 14.6 | 0.044 | |||||||
| EQ-5Dindex | 0.50 ± 0.4 | 0.58 ± 0.4 | 0.175 | 0.56 ± 0.4 | 0.340 | 0.59 ± 0.4 | 0.114 | |||||||
| EQ-5DVAS | 49.4 ± 21.4 | 58.9 ± 22.7 | 0.016 | 58.6 ± 20.6 | 0.015 | 58.7 ± 19.4 | 0.009 | |||||||
| MSFI-SF | 20.1 ± 22.1 | 14.4 ± 20.3 | 0.125 | 11.8 ± 17.2 | 0.022 | 10.8 ± 14.4 | 0.004 | |||||||
| Variables . | Baseline . | 1 mo . | P . | 2 mo . | P . | 4 mo . | P . | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Body weight (kg) | 55.1 ± 10 | 56.5 ± 10.5 | 0.001 | 56.4 ± 9.7 | 0.036 | 57 ± 9.8 | 0.031 | |||||||
| LBM (kg) | 38 ± 9 | 38.9 ± 9 | 0.059 | 39.4 ± 8.9 | 0.045 | 39.7 ± 8.7 | 0.024 | |||||||
| Grip strength (kg) | 28.0 ± 10.4 | 27.8 ± 9.5 | 0.879 | 27.9 ± 9.3 | 0.673 | 28.1 ± 9.5 | 0.827 | |||||||
| Appetite | 5.5 ± 2.5 | 6.6 ± 2.2 | 0.005 | 6.8 ± 1.9 | 0.001 | 7.0 ± 1.6 | 0.004 | |||||||
| IL-6 (pg/mL) | 12.5 ± 9.9 | 8.8 ± 8.7 | 0.002 | 7.5 ± 8.6 | 0.003 | 7.4 ± 8.5 | 0.007 | |||||||
| TNF-α (pg/mL) | 22.2 ± 16.6 | 19.5 ± 16 | 0.204 | 15.8 ± 13 | 0.020 | 14 ± 11.7 | 0.015 | |||||||
| Leptin (ng/mL) | 5.9 ± 6.1 | 8.9 ± 10.6 | 0.008 | 10.2 ± 13.3 | 0.031 | 13.6 ± 13.3 | <0.001 | |||||||
| ROS (FORT U) | 468.5 ± 97.2 | 436.6 ± 92.5 | 0.033 | 437.7 ± 89.6 | 0.087 | 444.1 ± 93.6 | 0.162 | |||||||
| GPx (units/L) | 8,206.6 ± 2,322.3 | 8,339.3 ± 2,411.8 | 0.726 | 8,295.9 ± 2,314.1 | 0.848 | 8,849.2 ± 2,629 | 0.211 | |||||||
| Quality of life questionnaires | ||||||||||||||
| EORTC QLQ-C30 | 65.9 ± 16.3 | 72.4 ± 15.6 | 0.008 | 71.8 ± 14.6 | 0.020 | 70.9 ± 14.6 | 0.044 | |||||||
| EQ-5Dindex | 0.50 ± 0.4 | 0.58 ± 0.4 | 0.175 | 0.56 ± 0.4 | 0.340 | 0.59 ± 0.4 | 0.114 | |||||||
| EQ-5DVAS | 49.4 ± 21.4 | 58.9 ± 22.7 | 0.016 | 58.6 ± 20.6 | 0.015 | 58.7 ± 19.4 | 0.009 | |||||||
| MSFI-SF | 20.1 ± 22.1 | 14.4 ± 20.3 | 0.125 | 11.8 ± 17.2 | 0.022 | 10.8 ± 14.4 | 0.004 | |||||||
NOTE: Data are reported as mean ± SD. As for EORTC QLQ-C30, EQ-5D index, and EQ-5DVAS, the increasing of score corresponds to improvement of quality of life, whereas for MSFI-SF, the decrease of quality of life score corresponds to amelioration of fatigue. Significance was considered for P < 0.05 as calculated with Student's t test for paired data (posttreatment values versus baseline values). Significance for IL-6, TNF-α, and leptin was calculated using Wilcoxon ranks test.
Abbreviations: GPx, glutathione peroxidase; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer QLQ-C30; EQ-5D, Euro QL-5D; MSFI-SF, multidimensional fatigue symptom inventory-short form.